Current Report Filing (8-k)
March 07 2017 - 4:36PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 7, 2017
PROTAGONIST THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-37852
|
|
98-0505495
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
Protagonist Therapeutics, Inc.
521 Cottonwood Drive, Suite 100
Milpitas, California 95035
(Address of principal executive offices, including zip code)
(408)
649-7370
(Registrants telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On March 7, 2017, Protagonist Therapeutics, Inc.
reported its financial results for the quarter and year ended December 31, 2016. A copy of the press release titled Protagonist Therapeutics Reports Fourth Quarter and
Year-End
2016 Financial
Results, is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
|
|
Exhibit
|
|
Description
|
|
|
99.1
|
|
Press release, dated March 7, 2017, titled Protagonist Therapeutics Reports Fourth Quarter and
Year-End
2016 Financial Results.
|
The information in this report, including the exhibit hereto, shall not be deemed to be filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying
exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Protagonist Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in
such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Protagonist Therapeutics, Inc.
|
|
|
|
Dated: March 7, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Thomas P. ONeil
|
|
|
|
|
|
|
Thomas P. ONeil
|
|
|
|
|
|
|
Chief Financial Officer
|
INDEX TO EXHIBITS
|
|
|
Exhibit
|
|
Description
|
|
|
99.1
|
|
Press release, dated March 7, 2017, titled Protagonist Therapeutics Reports Fourth Quarter and
Year-End
2016 Financial Results.
|
Protagonist Therapeutics (NASDAQ:PTGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Protagonist Therapeutics (NASDAQ:PTGX)
Historical Stock Chart
From Apr 2023 to Apr 2024